Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

392 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Proteomics-based identification of alpha-enolase as a tumor antigen in non-small lung cancer.
He P, Naka T, Serada S, Fujimoto M, Tanaka T, Hashimoto S, Shima Y, Yamadori T, Suzuki H, Hirashima T, Matsui K, Shiono H, Okumura M, Nishida T, Tachibana I, Norioka N, Norioka S, Kawase I. He P, et al. Among authors: hirashima t. Cancer Sci. 2007 Aug;98(8):1234-40. doi: 10.1111/j.1349-7006.2007.00509.x. Epub 2007 May 15. Cancer Sci. 2007. PMID: 17506794 Free PMC article.
Megakaryocyte potentiating factor as a tumor marker of malignant pleural mesothelioma: evaluation in comparison with mesothelin.
Iwahori K, Osaki T, Serada S, Fujimoto M, Suzuki H, Kishi Y, Yokoyama A, Hamada H, Fujii Y, Yamaguchi K, Hirashima T, Matsui K, Tachibana I, Nakamura Y, Kawase I, Naka T. Iwahori K, et al. Among authors: hirashima t. Lung Cancer. 2008 Oct;62(1):45-54. doi: 10.1016/j.lungcan.2008.02.012. Epub 2008 Apr 3. Lung Cancer. 2008. PMID: 18394747
Serum HE4 as a diagnostic and prognostic marker for lung cancer.
Iwahori K, Suzuki H, Kishi Y, Fujii Y, Uehara R, Okamoto N, Kobayashi M, Hirashima T, Kawase I, Naka T. Iwahori K, et al. Among authors: hirashima t. Tumour Biol. 2012 Aug;33(4):1141-9. doi: 10.1007/s13277-012-0356-9. Epub 2012 Feb 29. Tumour Biol. 2012. PMID: 22373583
Clinical significance of the serum crosslinked N-telopeptide of type I collagen as a prognostic marker for non-small-cell lung cancer.
Tamiya M, Kobayashi M, Morimura O, Yasue T, Nakasuji T, Satomu M, Kohei O, Takayuki S, Morishita N, Suzuki H, Sasada S, Okamoto N, Hirashima T, Kawase I. Tamiya M, et al. Among authors: hirashima t. Clin Lung Cancer. 2013 Jan;14(1):50-4. doi: 10.1016/j.cllc.2012.03.012. Epub 2012 May 18. Clin Lung Cancer. 2013. PMID: 22609050
Phase II tailored S-1 regimen study of first-line chemotherapy in elderly patients with advanced and recurrent non-small cell lung cancer.
Shiroyama T, Kijima T, Komuta K, Yamamoto S, Minami S, Ogata Y, Okafuji K, Imamura F, Hirashima T, Tachibana I, Kawase I, Kumanogoh A. Shiroyama T, et al. Among authors: hirashima t. Cancer Chemother Pharmacol. 2012 Dec;70(6):783-9. doi: 10.1007/s00280-012-1958-z. Epub 2012 Sep 9. Cancer Chemother Pharmacol. 2012. PMID: 22960985 Clinical Trial.
Randomized Phase II trial of paclitaxel and carboplatin followed by gemcitabine switch-maintenance therapy versus gemcitabine and carboplatin followed by gemcitabine continuation-maintenance therapy in previously untreated advanced non-small cell lung cancer.
Minami S, Kijima T, Shiroyama T, Okafuji K, Hirashima T, Uchida J, Imamura F, Osaki T, Nakatani T, Ogata Y, Yamamoto S, Namba Y, Otsuka T, Tachibana I, Komuta K, Kawase I. Minami S, et al. Among authors: hirashima t. BMC Res Notes. 2013 Jan 3;6:3. doi: 10.1186/1756-0500-6-3. BMC Res Notes. 2013. PMID: 23281805 Free PMC article. Clinical Trial.
392 results